Table 3.

Multivariate survival analysis for CD37 expression

OSPFS
HR95% CIPHR95% CIP
In overall DLBCL       
 Female sex 0.67 0.42-1.07 .09 0.74 0.48-1.15 .18 
 B symptoms 1.68 1.04-2.73 .035 1.69 1.06-2.68 .026 
 Tumor size ≥5 cm 1.32 0.83-2.09 .24 1.27 0.82-1.96 .28 
 IPI >2 2.35 1.49-3.70 <.001 2.43 1.57-3.75 <.001 
 ABC subtype 2.12 1.24-3.60 .006 1.79 1.08-2.98 .025 
 TP53 mutation 1.76 1.05-2.96 .033 1.68 1.02-2.75 .040 
 p63+ 0.71 0.47-1.07 .097 0.81 0.55-1.19 .29 
 p50high 1.09 0.70-1.71 .70 1.13 0.73-1.74 .58 
 CXCR4high 1.81 1.06-3.10 .03 2.15 1.28-3.63 .004 
 CD37+* 0.29 0.17-0.51 <.001 0.26 0.15-0.44 <.001 
 CD37– 3.43 1.96-6.02 <.001 3.91 2.28-6.71 <.001 
In GCB-DLBCL       
 Female sex 0.51 0.26-1.01 .053 0.57 0.31-1.06 .075 
 B symptoms 1.27 0.67-2.42 .46 1.16 0.65-2.10 .61 
 Tumor size ≥5 cm 1.65 0.88-3.08 .12 1.61 0.91-2.86 .10 
 IPI >2 3.66 1.90-7.01 <.001 3.39 1.90-6.06 <.001 
 TP53 mutation 1.36 0.64-2.89 .42 1.40 0.70-2.79 .35 
 p50high 0.77 0.35-1.69 .51 0.71 0.33-1.57 .40 
 p65high 1.90 0.81-4.46 .14 1.48 0.65-3.36 .35 
 p-STAT3high 0.73 0.28-1.89 .51 1.20 0.54-2.69 .65 
 MYC-R+ 3.01 1.06-3.98 .038 2.46 1.03-3.04 .043 
 Mychigh† 2.18 1.14-4.16 .018 1.67 0.90-3.08 .10 
 CD37+* 0.21 0.078-0.54 .001 0.18 0.073-0.43 <.001 
 CD37− 4.86 1.84-12.82 .001 5.64 2.32-13.74 <.001 
In ABC-DLBCL       
 Female sex 0.86 0.51-1.46 .58 0.94 0.57-1.55 .80 
 B symptoms 1.57 0.93-2.66 .098 1.52 0.91-2.54 .11 
 Tumor size ≥5 cm 1.31 0.77-2.24 .12 1.18 0.71-1.94 .53 
 IPI >2 2.75 1.65-4.56 <.001 2.76 1.58-4.82 <.001 
 p50high 1.87 1.10-3.16 .02 1.73 1.07-2.81 .027 
 Survivinhigh 1.61 0.89-2.88 .11 1.47 0.85-2.55 .17 
 CXCR4high 2.17 1.30-3.61 .003 1.90 1.11-3.24 .019 
 p63+ 0.58 0.34-1.00 .049 0.62 0.38-1.00 .048 
 CD37+* 0.39 0.23-0.67 .001 0.40 0.23-0.67 .001 
 CD37− 2.57 1.50-4.40 .001 2.53 1.50-4.44 .001 
In CD37+GCB-DLBCL       
 Female sex 0.25 0.016-4.08 .33 0.17 0.014-2.07 .17 
 B symptoms 2.13 0.17-27.3 .56 1.59 0.14-17.9 .71 
 Tumor size ≥5 cm 2.61 0.31-22.2 .38 1.44 0.24-8.62 .69 
 IPI >2 2.08 0.14-30.5 .60 2.01 0.14-28.0 .60 
 TP53 mutation 1.37 0.095-19.8 .82 3.17 0.35-28.8 .31 
 Mychigh 20.0 1.87-213.6 .013 14.1 1.39-143 .025 
 CXCR4high 5.45 0.61-48.7 .13 6.65 0.85-51.8 .071 
OSPFS
HR95% CIPHR95% CIP
In overall DLBCL       
 Female sex 0.67 0.42-1.07 .09 0.74 0.48-1.15 .18 
 B symptoms 1.68 1.04-2.73 .035 1.69 1.06-2.68 .026 
 Tumor size ≥5 cm 1.32 0.83-2.09 .24 1.27 0.82-1.96 .28 
 IPI >2 2.35 1.49-3.70 <.001 2.43 1.57-3.75 <.001 
 ABC subtype 2.12 1.24-3.60 .006 1.79 1.08-2.98 .025 
 TP53 mutation 1.76 1.05-2.96 .033 1.68 1.02-2.75 .040 
 p63+ 0.71 0.47-1.07 .097 0.81 0.55-1.19 .29 
 p50high 1.09 0.70-1.71 .70 1.13 0.73-1.74 .58 
 CXCR4high 1.81 1.06-3.10 .03 2.15 1.28-3.63 .004 
 CD37+* 0.29 0.17-0.51 <.001 0.26 0.15-0.44 <.001 
 CD37– 3.43 1.96-6.02 <.001 3.91 2.28-6.71 <.001 
In GCB-DLBCL       
 Female sex 0.51 0.26-1.01 .053 0.57 0.31-1.06 .075 
 B symptoms 1.27 0.67-2.42 .46 1.16 0.65-2.10 .61 
 Tumor size ≥5 cm 1.65 0.88-3.08 .12 1.61 0.91-2.86 .10 
 IPI >2 3.66 1.90-7.01 <.001 3.39 1.90-6.06 <.001 
 TP53 mutation 1.36 0.64-2.89 .42 1.40 0.70-2.79 .35 
 p50high 0.77 0.35-1.69 .51 0.71 0.33-1.57 .40 
 p65high 1.90 0.81-4.46 .14 1.48 0.65-3.36 .35 
 p-STAT3high 0.73 0.28-1.89 .51 1.20 0.54-2.69 .65 
 MYC-R+ 3.01 1.06-3.98 .038 2.46 1.03-3.04 .043 
 Mychigh† 2.18 1.14-4.16 .018 1.67 0.90-3.08 .10 
 CD37+* 0.21 0.078-0.54 .001 0.18 0.073-0.43 <.001 
 CD37− 4.86 1.84-12.82 .001 5.64 2.32-13.74 <.001 
In ABC-DLBCL       
 Female sex 0.86 0.51-1.46 .58 0.94 0.57-1.55 .80 
 B symptoms 1.57 0.93-2.66 .098 1.52 0.91-2.54 .11 
 Tumor size ≥5 cm 1.31 0.77-2.24 .12 1.18 0.71-1.94 .53 
 IPI >2 2.75 1.65-4.56 <.001 2.76 1.58-4.82 <.001 
 p50high 1.87 1.10-3.16 .02 1.73 1.07-2.81 .027 
 Survivinhigh 1.61 0.89-2.88 .11 1.47 0.85-2.55 .17 
 CXCR4high 2.17 1.30-3.61 .003 1.90 1.11-3.24 .019 
 p63+ 0.58 0.34-1.00 .049 0.62 0.38-1.00 .048 
 CD37+* 0.39 0.23-0.67 .001 0.40 0.23-0.67 .001 
 CD37− 2.57 1.50-4.40 .001 2.53 1.50-4.44 .001 
In CD37+GCB-DLBCL       
 Female sex 0.25 0.016-4.08 .33 0.17 0.014-2.07 .17 
 B symptoms 2.13 0.17-27.3 .56 1.59 0.14-17.9 .71 
 Tumor size ≥5 cm 2.61 0.31-22.2 .38 1.44 0.24-8.62 .69 
 IPI >2 2.08 0.14-30.5 .60 2.01 0.14-28.0 .60 
 TP53 mutation 1.37 0.095-19.8 .82 3.17 0.35-28.8 .31 
 Mychigh 20.0 1.87-213.6 .013 14.1 1.39-143 .025 
 CXCR4high 5.45 0.61-48.7 .13 6.65 0.85-51.8 .071 

Multivariate survival analysis for CD37 expression adjusting clinical factors and molecular biomarkers associated with CD37+/− in overall DLBCL, GCB-DLBCL, and ABC-DLBCL, and multivariate analysis in CD37+ GCB-DLBCL. The cutoffs for high/positive expression of p50, p65, p-STAT3, Myc, CXCR4, survivin, and p63 were ≥20%, ≥50%, ≥50%, ≥70%, ≥20%, >25%, and >5%, respectively. P values designating statistical significance, and the HR and 95% CI for CD37 status, are highlighted in bold.

*

Two different models were used to include either CD37+ or CD37− as 1 variant separately.

†

Two different Cox regression models were used to include either MYC-R+ or Mychigh as 1 variant separately. MYC rearrangement was not included as a variant in the multivariate analysis in CD37+ GCB-DLBCL because of limited case numbers.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal